


## NVP-TAE 226

## Chemical Properties

CAS No. :	761437-28-9
Formula:	C <sub>23</sub> H <sub>25</sub> ClN <sub>6</sub> O <sub>3</sub>
Molecular Weight:	468.94
Storage:	Powder: -20°C for 3 years   In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



## Biological Description

Description	NVP-TAE 226 (TAE226) is a potent FAK inhibitor (IC <sub>50</sub> : 5.5 nM), exhibiting even greater efficacy against Pyk2 (IC <sub>50</sub> : 3.5 nM), and is 10- to 100-fold less effective against IGF-1R, InsR, c-Met, and ALK.
Targets(IC <sub>50</sub> )	Apoptosis,FAK,PYK2,c-Met/HGFR,IGF-1R
In vitro	In in vivo models, NVP-TAE226 (100 mg/kg, p.o.) significantly hindered the growth of human pancreatic tumor MIA PaCa-2 without affecting body weight. Moreover, NVP-TAE226 demonstrated a dose-dependent inhibition of growth and lung metastasis in 4T1 murine mammary tumors, correlated with the suppression of FAK autophosphorylation on Y397 and Akt phosphorylation on serine 473. At a dosage of 75 mg/kg, NVP-TAE226 significantly increased the survival rate of mice bearing intracranial glioma xenografts. Additionally, in a human colorectal cancer SCID mouse model, NVP-TAE226 (100 mg/kg, p.o.) markedly reduced microvessel density.
In vivo	NVP-TAE226 (0.1-10 μM) inhibits microtubule formation in HMEC1 cells and suppresses serum starvation-induced autophosphorylation of FAK(Tyr397) in U87 cells at concentrations below 1 μM. It also inhibits IGF-I-induced phosphorylation of IGF-1R and its downstream target gene activities, including MAPK and Akt in U87 and U251 cells at concentrations under 1 μM. Moreover, NVP-TAE226 at 1 μM inhibits tumor cell invasion by more than 50% in vitro assays on an artificial basement membrane for glioblastoma cell lines. It induces G(2)-M phase arrest in glioblastoma cell lines, including those with wild-type p53, while those bearing mutant p53 undertake apoptosis, evidenced by the activation of caspase-3/7, poly(ADP-ribose) polymerase cleavage, and annexin V apoptosis assays. In the neuroblastoma cell line SK-N-AS, NVP-TAE226 at 5 μM inhibits FAK phosphorylation and at concentrations below 10 μM decreases cell viability, induces cell cycle arrest, and increases apoptosis. In U87 and U251 cells, it impedes tumor cell growth and weakens the G(2)-M cell cycle process related to reduced expression of cyclin B1 and phosphorylated cdc2(Tyr15) proteins at concentrations
Kinase Assay	Kinase assay: Kinase activities are assayed in Buffer A or C at 30°C, at a final ATP concentration of 15 μM. Blank values are subtracted and activities calculated as pmoles of phosphate incorporated during a 10 min incubation. Controls are performed with appropriate dilutions of dimethylsulfoxide. In a few cases phosphorylation of the substrate is assessed by autoradiography after SDS-PAGE. GSK-3α/β is purified from porcine brain by affinity chromatography on immobilized axin. It is assayed, following a 1/100 dilution in 1 mg BSA/ml 10 mM DTT, with 5 μl 40 μM GS-1 peptide, a specific GSK-3

## A DRUG SCREENING EXPERT

Kinase Assay	substrate, (YRRAAVPPSPSLSRHSSPHQSpEDEEE), in buffer A, in the presence of 15 $\mu$ M [ $\gamma$ - <sup>32</sup> P] ATP (3,000 Ci/mmol; 1 mCi/ml) in a final volume of 30 $\mu$ l. After 30 min incubation at 30°C, 25 $\mu$ l aliquots of supernatant are spotted onto 2.5 $\times$ 3 cm pieces of Whatman P81 phosphocellulose paper, and 20 seconds later, the filters are washed five times (for at least 5 min each time) in a solution of 10 ml phosphoric acid/liter of water. The wet filters are counted in the presence of 1 ml ACS scintillation fluid.
Cell Research	Cell cultures are harvested with 0.05% trypsin and seeded in triplicate at $2 \times 10^4$ in 24-well culture plates for 24 h before drug treatment. Culture medium is used for mock treatment. Cells are harvested at the indicated day after treatment, and viable cells are counted using the Vi-cell viability analyze(Only for Reference)

### Solubility Information

Solubility	DMSO: 87 mg/mL (185.52 mM),Sonication is recommended. Ethanol: < 1 mg/mL (insoluble or slightly soluble), H2O: < 1 mg/mL (insoluble or slightly soluble), (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Corn Oil: 1 mg/mL (2.13 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1325 mL	10.6623 mL	21.3247 mL
5 mM	0.4265 mL	2.1325 mL	4.2649 mL
10 mM	0.2132 mL	1.0662 mL	2.1325 mL
50 mM	0.0426 mL	0.2132 mL	0.4265 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

Liu TJ, et al. Mol Cancer Ther, 2007, 6(4), 1357-1367.

Sang M, Luo R, Bai Y, et al. BHQ-Cyanine-Based "Off-On" Long-Circulating Assembly as a Ferroptosis Amplifier for Cancer Treatment: A Lipid-Peroxidation Burst Device. ACS Applied Materials & Interfaces. 2019, 11(46): 42873-42884

Zheng Q, Zou Y, Teng P, et al. Mechanosensitive Channel PIEZO1 Senses Shear Force to Induce KLF2/4 Expression via CaMKII/MEKK3/ERK5 Axis in Endothelial Cells. Cells. 2022, 11(14): 2191

Beierle EA, et al. Cancer Invest, 2008, 26(2), 145-151.

Schultze A, et al. Invest New Drugs, 2010, 28(6), 825-833.

Su Y, Li R, Ning X, et al. Discovery of 2, 4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities. European Journal of Medicinal Chemistry. 2019 May 18;177:32-46

Li R, Gong L, Sun J, et al. Discovery of 2, 4-diarylaminopyrimidine derivatives bearing sulfonamide moiety as novel FAK inhibitors. Bioorganic Chemistry. 2024: 107134.

Su Y, Li R, Ning X, et al. Discovery of 2, 4-diarylaminopyrimidine derivatives bearing dithiocarbamate moiety as novel FAK inhibitors with antitumor and anti-angiogenesis activities[J]. European Journal of Medicinal Chemistry. 2019 May 18;177:32-46.

Zhang H, Chen J, Meng Y, et al. Overexpression of Pin1 regulated by TOP2A, which subsequently stabilizes Pyk2 to promote bortezomib resistance in multiple myeloma. Cancer Gene Therapy. 2024: 1-16.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E\_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481